Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Clinical trial NCT01497093 · COMPLETED
Trial details
- NCT number
- NCT01497093
- Sponsor
- Celgene
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2012-02-15
- Primary completion
- 2019-07-23
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.